Sample result
A saved result, shown read-only. Sign in to run your own searches. A new account gets a free 30-day trial.
GLP-1, a diabetes hormone
Protein → Patent proteins · Automatic (Smith-Waterman)
Every list and the search record, one sheet each.
- Query
- GLP-1 · 31 lettersHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
- Set
- Public patent sequences: Patent proteins, snapshot 2026-11-05-c456f6bdba29
- Ran
- 2026-11-12
- Found
- 5,000 sequences, 3,061 publications, 1,851 families
Charts
Identity against coverage
5,000 hits by identity and query coverage. 5,000 with a date.
Show table
| Band | Has a date | All |
|---|---|---|
| 100% | 553 | 553 |
| 95 to 99.9% | 992 | 992 |
| 90 to 94.9% | 2,638 | 2,638 |
| 80 to 89.9% | 814 | 814 |
| 70 to 79.9% | 3 | 3 |
| Band | Has a date | All |
|---|---|---|
| 100% | 3,606 | 3,606 |
| 95 to 99.9% | 876 | 876 |
| 90 to 94.9% | 483 | 483 |
| 80 to 89.9% | 35 | 35 |
Hits by year
3,061 publications by year of first publication, 1990 to 2026.
Show table
| Year | Has a date | All |
|---|---|---|
| 1990 | 2 | 2 |
| 1992 | 2 | 2 |
| 1993 | 1 | 1 |
| 1994 | 1 | 1 |
| 1995 | 1 | 1 |
| 1996 | 3 | 3 |
| 1997 | 2 | 2 |
| 1998 | 2 | 2 |
| 1999 | 11 | 11 |
| 2000 | 13 | 13 |
| 2001 | 20 | 20 |
| 2002 | 37 | 37 |
| 2003 | 33 | 33 |
| 2004 | 37 | 37 |
| 2005 | 54 | 54 |
| 2006 | 62 | 62 |
| 2007 | 77 | 77 |
| 2008 | 81 | 81 |
| 2009 | 107 | 107 |
| 2010 | 101 | 101 |
| 2011 | 110 | 110 |
| 2012 | 121 | 121 |
| 2013 | 123 | 123 |
| 2014 | 135 | 135 |
| 2015 | 142 | 142 |
| 2016 | 144 | 144 |
| 2017 | 157 | 157 |
| 2018 | 149 | 149 |
| 2019 | 150 | 150 |
| 2020 | 156 | 156 |
| 2021 | 183 | 183 |
| 2022 | 161 | 161 |
| 2023 | 175 | 175 |
| 2024 | 181 | 181 |
| 2025 | 231 | 231 |
| 2026 | 96 | 96 |
Where hits align on the query
The top 20 hits on GLP-1, a query of 31 amino acids: 20 cover the whole query, none differs from it.
Show table
| Hit | Query from | Query to | Identity | Differs at | Gaps at | X at |
|---|---|---|---|---|---|---|
| AAA55132.1 | 1 | 31 | 100.0% | None | None | None |
| A31422.1 | 1 | 31 | 100.0% | None | None | None |
| AAB11984.1 | 1 | 31 | 100.0% | None | None | None |
| DI506186 | 1 | 31 | 100.0% | None | None | None |
| DI527435 | 1 | 31 | 100.0% | None | None | None |
| AAB11995.1 | 1 | 31 | 100.0% | None | None | None |
| AAE02614.1 | 1 | 31 | 100.0% | None | None | None |
| DI540976 | 1 | 31 | 100.0% | None | None | None |
| DI521338 | 1 | 31 | 100.0% | None | None | None |
| DI502216 | 1 | 31 | 100.0% | None | None | None |
| DJ789879 | 1 | 31 | 100.0% | None | None | None |
| DI520483 | 1 | 31 | 100.0% | None | None | None |
| AAE49428.1 | 1 | 31 | 100.0% | None | None | None |
| AAE49430.1 | 1 | 31 | 100.0% | None | None | None |
| AAE49429.1 | 1 | 31 | 100.0% | None | None | None |
| AAE49432.1 | 1 | 31 | 100.0% | None | None | None |
| DI501808 | 1 | 31 | 100.0% | None | None | None |
| AAY78103.1 | 1 | 31 | 100.0% | None | None | None |
| BD613525 | 1 | 31 | 100.0% | None | None | None |
| BD613528 | 1 | 31 | 100.0% | None | None | None |
Patents 3.1K
3,061 publications from 692 applicants, 83 with no applicant, match these filters.
Eli Lilly and Company 205 publications, continued
-
JP 2022043082-A2022-03-15
INCRETIN ANALOGS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020220035199-A2022-03-21
METHODS OF MAKING INCRETIN ANALOGS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2022519620-A2022-03-24
GLUCAGON ANALOG AGONISTS AND METHODS OF USING THE SAME
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020220100676-A2022-07-15
INCRETIN ANALOGS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020220131292-A2022-09-27
GIP/GLP1 CO-AGONIST COMPOUNDS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020220133304-A2022-10-04
INCRETIN ANALOGS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2022544061-A2022-10-17
GIPR-Agonist Compounds
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2022545200-A2022-10-26
METHODS OF MAKING INCRETIN ANALOGS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2022177118-A2022-11-30
METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 11542313-B22023-01-03
Incretin analogs and uses thereof
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020230023822-A2023-02-17
GIP AND GLP-1 CO-AGONIST COMPOUNDS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2023506952-A2023-02-20
INCRETIN ANALOGS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2023511441-A2023-03-17
GIP/GLP1 Co-Agonist Compounds
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2023062068-A2023-05-02
GIPR-Agonist Compounds
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020230146645-A2023-10-19
INCRETIN ANALOG-CONTAINING COMPOSITIONS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2023171775-A2023-12-05
GIP/GLP1 CO-AGONIST COMPOUNDS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 11834486-B22023-12-05
Incretin analogs and uses thereof
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 11897926-B22024-02-13
GIPR-agonist compounds
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2024508745-A2024-02-28
GIP/GLP1 Dual Agonist Therapeutic Methods
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2024513754-A2024-03-27
INCRETIN ANALOG-CONTAINING COMPOSITIONS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020240051304-A2024-04-19
GIP/GLP1 CO-AGONIST COMPOUNDS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2024056852-A2024-04-23
METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020240095310-A2024-06-25
METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020240135032-A2024-09-10
GIP AND GLP-1 CO-AGONIST COMPOUNDS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2024147650-A2024-10-16
METHODS OF MAKING INCRETIN ANALOGS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2024150523-A2024-10-23
GIPR-Agonist Compounds
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 12252524-B22025-03-18
GIP/GLP1 co-agonist compounds
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2025063146-A2025-04-15
METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020250065721-A2025-05-13
GIPR-AGONIST COMPOUNDS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 12295987-B22025-05-13
Method of using a GIP/GLP1 co-agonist for diabetes
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020250074694-A2025-05-27
METHODS OF MAKING INCRETIN ANALOGS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2025093970-A2025-06-24
INCRETIN ANALOGS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 12365716-B22025-07-22
Incretin analogs and uses thereof
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 12371465-B22025-07-29
Incretin analogs and uses thereof
ELI LILLY AND COMPANY
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2025531200-A2025-09-19
GIP AND GLP-1 DUAL AGONIST COMPOUNDS
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020250140094-A2025-09-24
GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 12453758-B22025-10-28
Method of using a GIP/GLP1 co-agonist for diabetes
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
WO 2026024920-A12026-01-29
Fc-ACYLATED POLYPEPTIDE CONJUGATES
ELI LILLY AND COMPANY
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2026016447-A2026-02-03
GIP/GLP1 Dual Agonist Therapeutic Methods
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2026505071-A2026-02-10
GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF
ELI LILLY AND COMPANY
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2026031900-A2026-02-25
FC-ACYLATED POLYPEPTIDE CONJUGATES
ELI LILLY AND COMPANY
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2026069790-A2026-04-24
GIP/GLP1 CO-AGONIST COMPOUNDS
ELI LILLY AND COMPANY
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
JP 2026102658-A2026-06-23
INCRETIN ANALOG-CONTAINING COMPOSITIONS AND USES THEREOF
Eli Lilly and Company
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
KR 1020230137987-A2023-10-05
LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF
Eli Lilly and Company
Query Match 95.7%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||||||||||||||| ||| Hit 1 HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG 3129 of 31 identical, no gaps.
-
JP 2024508312-A2024-02-26
LONG ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF
Eli Lilly and Company
Query Match 95.7%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||||||||||||||| ||| Hit 1 HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG 3129 of 31 identical, no gaps.
-
US 12115210-B22024-10-15
Long acting amylin receptor agonists and uses thereof
Eli Lilly and Company
Query Match 95.7%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||||||||||||||| ||| Hit 1 HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG 3129 of 31 identical, no gaps.
-
JP 2025090588-A2025-06-17
LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF
Eli Lilly and Company
Query Match 95.7%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||||||||||||||| ||| Hit 1 HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG 3129 of 31 identical, no gaps.
-
JP 2025148269-A2025-10-07
LEPTIN RECEPTOR AGONISTIC ANTIBODY AS MONO OR COMBO THERAPIES TO TREAT OBESITY
Eli Lilly and Company
Query Match 95.7%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||||||||||||||| ||| Hit 1 HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG 3129 of 31 identical, no gaps.
-
US 12551532-B22026-02-17
Long-acting amylin receptor agonists and uses thereof
Eli Lilly and Company
Query Match 95.7%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||||||||||||||| ||| Hit 1 HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG 3129 of 31 identical, no gaps.
-
WO 0247716-A22002-06-20
Chronic treatment regimen using glucagon-like insulinotropic peptides
ELI LILLY AND COMPANY (US)
Query Match 93.8%Identity 96.7%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 | |||||||||||||||||||||||||||| Hit 1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3029 of 30 identical, no gaps.